Vibozone Pharmaceuticals Signs Partnership Agreement with Daiichi Sankyo Korea for "Anapraju"

Vibozone Pharmaceuticals announced on September 16 that it has officially selected Daiichi Sankyo Korea Co., Ltd. as its joint promotion partner for "Anapraju" (ingredient: Opranzerin Hydrochloride), the 38th domestically developed new drug and a non-narcotic analgesic, and will begin full-scale domestic sales.

Jang Buhwan, CEO of Vibozone Pharmaceuticals (left), and Kim Jungtae, CEO of Korea Daiichi Sankyo, are holding a commemorative photo after signing a joint promotion contract for the non-narcotic analgesic 'Onapraju' on the 15th. Vibozone Pharmaceuticals

The two companies signed a strategic collaboration on September 15 for the domestic distribution, marketing, and sales of the non-narcotic analgesic Anapraju. Vibozone Pharmaceuticals will supply finished Anapraju products to Daiichi Sankyo Korea, and both companies plan to share responsibilities in distribution, sales, and marketing.

Daiichi Sankyo Korea is the Korean subsidiary of Daiichi Sankyo, a global healthcare company with over 120 years of history. The company has a differentiated product portfolio in the anesthesia and pain management fields and operates a nationwide specialized sales organization. Its flagship products include "NazeA" (Ramosetron) for the prevention of nausea and vomiting, and "Talize" (Mirogabalin) for the treatment of neuropathic pain.

Anapraju was approved in December last year by the Ministry of Food and Drug Safety as the 38th domestically developed new drug. It features a novel mechanism that simultaneously inhibits glycine transporter type 2 (GlyT2) and serotonin receptor type 2A (5-HT2A), thereby blocking pain transmission in both the central and peripheral nervous systems.

In particular, unlike existing narcotic analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), Anapraju is less likely to cause side effects such as addiction and gastrointestinal disorders, making it a promising new option for pain management. Additionally, despite being a non-narcotic analgesic, it is notable for its ability to control moderate to severe postoperative pain.

Jang Buhwan, CEO of Vibozone Pharmaceuticals, stated, "We expect Anapraju to quickly establish itself in the market based on Daiichi Sankyo Korea's robust domestic hospital and clinic distribution network. As the misuse of narcotic analgesics becomes a social issue and demand for non-narcotic painkillers increases, we will strive to supply Anapraju promptly to help improve patients' quality of life."

This content was produced with the assistance of AI translation services.